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Aim To perform a comprehensive evaluation of associa-
tion of common genetic variants in candidate genes in 
the dopaminergic pathway with schizophrenia in a sample 
from Croatian population.
Methods A case-control association study was performed 
on 104 unrelated patients with schizophrenia recruited 
from a psychiatric hospital in Zagreb and 131 phenotyp-
ically normal Croatian subjects. Forty-nine tagging single 
nucleotide polymorphisms (tagSNPs) in 8 candidate genes 
in the dopaminergic pathway were identified from the 
HapMap database and tested for association. Genotyping 
was performed using the SNPlex platform. Statistical analy-
sis was conducted to assess allelic and genotypic associa-
tions between cases and controls using a goodness of fit 
χ2 test and trend test, respectively; adjustment for multiple 
testing was done by permutation based analysis.
Results Significant allele frequency differences between 
schizophrenia cases and controls were observed at 4 tag-
SNPs located in the genes DRD5, HTR1B1, DBH, and TH1 
(P < 0.005). A trend test also confirmed the genotypic asso-
ciation (P < 0.001) of these 4 tagSNPs. Additionally, moder-
ate association (P < 0.05) was observed with 8 tagSNPs on 
SLC6A3, DBH, DRD4, SLC6A4, and COMT.
Conclusions Common genetic variants in genes involved 
in the dopaminergic pathway are associated with schizo-
phrenia in the populations of Caucasian descent.
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Schizophrenia is a chronic, severe, and disabling brain dis-
ease affecting about 1% of the global population (1). There 
is substantial evidence that genetic factors are involved 
in the etiology of the disease (2). High heritability ( ~ 80%) 
and higher concordance in monozygotic ( ~ 50%) than in 
dizygotic ( ~ 17%) twins are strong indicators for an inher-
ited basis of schizophrenia (3-5). During the past decade, 
numerous loci and plausible candidate genes have been 
identified by linkage and association studies. However, the 
findings have remained inconclusive (2,6). Like other com-
plex diseases, a complex genetic etiology compounded 
by involvement of other non-genetic factors has hindered 
the precise identification of schizophrenia gene variants. 
Second, a major limitation in most association studies has 
been testing of a few variants within a gene of interest 
rather than a thorough assessment of the entire gene re-
gion. With the availability of the sequence of the genome 
and large body of data on human genetic variation from 
the HapMap project (7), it is now possible to undertake 
more comprehensive association studies.
Genes involved in the dopamine pathway are biologically 
plausible candidates in schizophrenia susceptibility. In this 
study, we report on the association of single nucleotide 
polymorphisms (SNPs) in 8 dopaminergic genes (DRD4, 
DRD5, SLC6A3, SLC6A4, HTR1B, DBH, TH, and COMT) with 
schizophrenia in a Caucasian sample from Croatia. We per-
formed a comprehensive association study using tagging 
SNPs (tagSNPs). Overall, 49 tagSNPs were identified from 
the HapMap database (7), 4 of which showed strong evi-
dence of association with schizophrenia susceptibility.
MATeRiAlS AND MeTHoDS
Subjects
Cases, consisting of 104 unrelated individuals (61 men and 
43 women) of Croatian ancestry were recruited from the 
Jankomir hospital in Zagreb, Croatia. Diagnoses, which 
were coded according to ICD-10 (8), included general 
schizophrenia and 4 subtypes of schizophrenia that all be-
long to a wider group of schizophrenia disorders (ICD-10 
codes F20-F20.9). Of the 104 participants (Table 1), general 
schizophrenia (ICD-10 code F20) was assigned to 3 indi-
viduals (excluding acute schizophrenia-like psychotic dis-
order [F23.2], undifferentiated schizophrenia [F20.3], cyclic 
schizophrenia [F25.2], and schizotypal disorder [F21]). Alto-
gether 59 subjects suffered from paranoid schizophrenia 
(ICD-10 code F20.0), 36 from residual schizophrenia (ICD-
10 code F20.5), 3 from hebephrenic schizophrenia (ICD-10 
code F20.1), and 3 from simple schizophrenia (ICD-10 code 
F20.6). Mean age of the subjects were 43.6 ± 10.6 years, 
with a range of 23-74 years. Age at the onset of the disease 
was not available.
For controls, blood samples were obtained from 131 phe-
notypically healthy unrelated Croatian individuals, who 
were recruited as volunteers in anthropological field sur-
veys. Control individuals were sampled from Zagreb and 
6 other cities representing 6 geographically dispersed re-
gions of mainland Croatia. Mean age of the controls was 
50.3 ± 7.5, with a range of 30-74 years.
DNA analysis
Cases’ DNA was isolated from whole blood (7 mL) by either 
Nucleon® Genomic DNA Extraction Kit (Tepnel Life Scienc-
es PLC, Manchester, UK) standard protocols or by protocol 
of salting-out method given by Miller et al (9). DNA sam-
ples of control group were extracted from whole blood 
samples using the chloroform-phenol extraction method, 
previously described by Ponz et al (10). DNA was suspend-
ed in TE-buffer for use in genotyping.
The candidate genes, their chromosomal map positions, 
and the number of tagSNPs are listed in Table 2. TagSNPs 
were selected using the tagging approach of Carlson et 
al (11) implemented in the SNPbrowser Software, version 
3.5 (Applied Biosystems, Foster City, CA, USA). As the study 
population is of European descent, we used the Caucasian 
HapMap database (7) based on pairwise r2 (≥0.8) among all 
common SNPs with minor allele frequency (MAF)≥0.05 for 
selection of the tagSNPs. Altogether 49 SNPs tagged the 8 
candidate genes.
Genotyping was performed on the SNPlex platform. The 
SNPlex Genotyping System is based on multiple oligo-
nucleotide ligation/PCR assay with a universal ZipChute 
probe detection for high-throughput multiplexed SNP 
genotyping. Fluorescently labeled ZipChute probes were 
TAble 1. Summary of cases and their diagnosis
Diagnosis* (iCD-10 code) Male Female Total
General schizophrenia (F20)  3  0   3
Paranoid schizophrenia (F20.0) 32 27  59
Hebephrenic schizophrenia (F20.1)  3  0   3
Residual schizophrenia (F20.5) 23 13  36
Simple schizophrenia (F20.6)  0  3   3
Total 61 43 104
*According to iCD-10 (8).
363Pal et al: Candidate Gene Variants and Schizophrenia
www.cmj.hr
hybridized to complementary ZipCode sequences that 
were part of genotype-specific amplicons. These ZipChute 
probes were eluted and detected by electrophoretic sepa-
ration on Applied Biosystems 3130 DNA Analyzer. The Gen-
eMapper® software version 3.7 was used for automated al-
lele calling for all SNPs.
Statistical analysis
Allele frequencies were estimated by gene counting. Con-
formity of genotype proportions to Hardy-Weinberg ex-
pectations (HWE) was performed by the exact test (12). 
Allelic association between cases and controls was per-
formed using a goodness of fit χ2 test and adjustment for 
multiple testing was performed by permuting the associa-
tion results 10 000 times to define the smallest empirical 
significance level (13). We used the PLINK whole genome 
analysis toolset (version 1.0.6) for allelic and genotypic as-
sociation (trend test) and for inferring age-adjusted odds 
ratios (OR) (14).
ReSulTS
The results of allelic and genotypic associations are sum-
marized in Table 3. This table presents the genomic base 
positions of the tagSNPs, MAFs in cases and controls, HWE 
P-values and the permuted P-values for allelic association 
with schizophrenia susceptibility, and trend test P-val-
ues for primary comparisons of genotypes. There was no 
deviation from the expectations of HWE at any SNP. We 
found a significant association of 4 tagSNPs located one 
each in DRD5 (rs1850744, P = 0.002), HTR1B1 (rs2143823, 
P = 0.005), DBH (rs2007153, P < .001), and TH (rs4320932, 
P < .001). MAFs at these 4 SNPs differed by >10% between 
schizophrenia cases and controls. Additionally, modest 
allele frequency differences and significant association 
(allele frequency difference <10%) was observed with 8 
tagSNPs on SLC6A3 (rs464049, P = 0.045), DBH (rs2283123, 
P = 0.039), DRD4 (rs11246226, P = 0.014; and rs4331145, 
P = 0.038), SLC6A4 (rs140700, P = 0.037; and rs1050565, 
P = 0.034), and COMT (rs2020917, P = 0.037; and rs165815, 
P = 0.021). We then performed logistic regression to infer 
the age- and sex-adjusted OR and their respective 95% 
confidence intervals for the 12 significant tagSNPs that 
showed association at allelic level (Table 4). All of the 4 
significantly associated tagSNPs showed significant asso-
ciations of genotypes under one or more of the inherited 
models (additive, dominant, recessive, and log-additive), 
providing additional confirmation of the findings. Four of 
the 8 tagSNPs with modest associations (rs464049 in SL-
C6A3, rs11246226 and rs4331145 in DRD4, and rs2020917 
in COMT) also showed associations under one or more of 
the genetic models.
As case-control design can result in spurious associa-
tion due to population stratification (15), we performed 
a structure analysis (16) using a set of 86 SNPs distribut-
ed over 11 chromosomes. We did not find evidence for 
substructure in our case-control population (data not 
shown).
DiSCuSSioN
This study reports the association of tagSNPs in 8 candi-
date genes involved in the dopaminergic pathway with 
schizophrenia in a Caucasian sample from Croatia. The 
analysis revealed significant allele and genotype frequen-
cy differences between the schizophrenia cases and con-
trols at 4 tagSNPs located in DRD5, HTR1B, DBH, and TH. In 
addition, moderate levels of association were observed 
with 8 tagSNPs in SLC6A3, DBH, DRD4, SLC6A4, and COMT. 
These results reaffirm that common sequence variants in 
dopaminergic genes are associated with susceptibility to 
schizophrenia in populations of Caucasian descent.
TAble 2. Candidate genes, map locations, and tagging single nucleotide polymorphisms (SNP)
Gene symbol Gene name Map position No. of tagSNPs
DRD5 dopamine receptor D5 4p16.1  3
SLC6A3 solute carrier family 6 member 3 5p15.3  8
HTR1B 5 hydroxytryptamine (serotonin) receptor 1B 6q13  5
DBH dopamine beta-hydroxylase 9q34.2  8
DRD4 dopamine receptor D4 11p15.5  4
TH tyrosine hydroxylase isoform a 11p15.5  5
SLC6A4 solute carrier family 6 member 4 17q11.1-q12  4
COMT catechol-O-methyltransferase isoform MB-COMT 22q11.21 12
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TAble 3. Allelic and genotypic associations on 8 genes with schizophrenia susceptibility*





















DRD5 (4p16.1) rs10033951 C/T 9455849 0.151 0.278 0.223  1.296 0.255 0.316
rs2867383 A/G 9464204 1 0.018 0.005  1.439 0.230 0.364
rs1850744 A/G 9466981 0.466 0.179 0.071  9.713 0.002 0.001
SLC6A3 (5p15.3) rs40184 A/G 1448077 0.01 0.452 0.39  1.138 0.286 0.438
rs11133767 A/G 1454580 0.149 0.239 0.196  0.787 0.375 0.473
rs6869645 C/T 1457548 0.643 0.098 0.064  1.283 0.257 0.398
rs37022 A/T 1468629 0.532 0.25 0.275  0.244 0.622 0.851
rs464049 C/T 1476905 0.725 0.355 0.465  4.015 0.045 0.005
rs460000 A/C 1485825 0.112 0.283 0.256  0.169 0.681 0.565
rs403636 G/T 1491354 1 0.05 0.02  2.547 0.111 0.255
rs3756450 C/T 1501148 0.969 0.212 0.195  0.151 0.698 0.805
HTR1B (6q13) rs2143823 C/T 78219236 0.05 0.41 0.244  7.985 0.005 0.001
rs9359271 A/C 78222839 0.139 0.349 0.368  0.110 0.740 0.714
rs2000292 A/G 78223664 0.815 0.272 0.309  0.534 0.465 0.924
rs6297 A/G 78228660 1 0.159 0.1  2.759 0.097 0.182
rs1213371 C/T 78236764 0.03 0.358 0.371  0.041 0.839 0.745
DBH (9q34.2) rs1076150 A/G 133528315 0.325 0.367 0.429  1.377 0.241 0.066
rs1611115 C/T 133530069 1 0.733 0.774  0.751 0.386 0.643
rs2007153 A/G 133533373 1 0.470 0.658 11.135 0.001 0.0004
rs3025399 A/C 133538528 0.971 0.113 0.119  0.019 0.889 0.774
rs1541333 C/G 133540939 0.837 0.442 0.480  0.459 0.498 0.716
rs2283123 C/T 133544851 0.422 0.063 0.020  4.274 0.039 0.050
rs77905 C/T 133547651 0.454 0.475 0.475  0.000 0.999 0.763
rs732833 A/G 133550216 0.118 0.416 0.335  2.268 0.132 0.221
DRD4 (11p15.5) rs3758653 C/T 626399 0.019 0.395 0.450  0.421 0.517 0.526
rs11246226 A/C 631191 0.736 0.183 0.078  6.100 0.014 0.016
rs936465 C/G 633568 0.417 0.395 0.352  0.267 0.606 0.697
rs4331145 A/G 633683 0.039 0.327 0.202  4.298 0.038 0.031
TH (11p15.5) rs4320932 A/G 2128177 0.555 0.236 0.065 12.305 0.001 0.0003
rs7924316 G/T 2130023 0.702 0.455 0.456  0.000 0.985 0.550
rs3842748 C/G 2137971 0.001 0.442 0.468  0.199 0.655 0.774
rs2070762 C/T 2142911 1 0.389 0.446  1.036 0.309 0.142
rs7396243 G/T 2162468 0.208 0.355 0.41  1.042 0.307 0.218
SLC6A4 (17q11.1-q12) rs3794808 A/G 25555919 1 0.204 0.257  1.754 0.185 0.055
rs140700 A/G 25567515 0.049 0.143 0.078  4.349 0.037 0.062
rs2066713 C/T 25575791 0.778 0.421 0.417  0.007 0.936 0.805
rs1050565 A/G 25600202 0.641 0.323 0.434  4.496 0.034 0.038
COMT (22q11.21) rs2020917 C/T 18303438 0.917 0.460 0.581  4.376 0.037 0.122
rs933271 C/T 18305961 0.382 0.407 0.479  1.514 0.219 0.084
rs1544325 A/G 18306222 0.06 0.452 0.454  0.001 0.972 0.925
rs5992500 C/T 18316501 1 0.008 0.006  0.077 0.782 0.125
rs740603 A/G 18319731 0.085 0.352 0.272  1.943 0.163 0.177
rs165656 C/G 18323417 0.06 0.434 0.357  1.607 0.205 0.193
rs4646316 C/T 18326686 0.935 0.156 0.097  1.889 0.169 0.087
rs165774 A/G 18327115 0.279 0.433 0.454  0.106 0.744 0.982
rs174696 C/T 18327730 0.506 0.412 0.375  0.209 0.648 0.5
rs174697 A/G 18328386 1 0.075 0.081  0.040 0.842 0.685
rs165728 C/T 18331577 0.07 0.125 0.062  3.210 0.073 0.465
rs16581)5 C/T 18334027 0.244 0.298 0.449  5.357 0.021 0.142
*Abbreviations: SNPs – single nucleotide polymorphism; NCbi – National Center for biotechnology information; Pχ2 – P-value from χ
2 test for allelic 
frequency differences; PTrend – P-value from genotypic trend test; HWe – Hardy Weinberg expectations.
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TAble 4. Genotypic associations of 12 significant tag single nucleotide polymorphisms (tagSNP) with schizophrenia susceptibility
Genotype Frequency odds ratio
SNP model Genotypes control case (95% confidence interval) P
rs1850744 (DRD4) additive G/G 0.67 0.86 1
<0.001A/G 0.27 0.14 0.37 (0.17-0.82)
A/A 0.06 0.00
dominant G/G 0.67 0.86 1
 0.002
A/G-A/A 0.33 0.14 0.30 (0.14-0.66)
recessive G/G-A/G 0.94 1.00 1
 0.005
A/A 0.06 0.00
log-additive 0.30 (0.15-0.62) <0.001
rs464049 (SLC6A3) additive C/C 0.52 0.28 1
<0.001C/T 0.33 0.56 3.62 (1.87-7.02)
T/T 0.14 0.17 2.37 (0.99-5.68)
dominant C/C 0.52 0.28 1
<0.001
C/T-T/T 0.48 0.72 3.23 (1.74-5.97)
recessive C/C-C/T 0.86 0.83 1
 0.641
T/T 0.14 0.17 1.21 (0.55-2.67)
log-additive 1.84 (1.21-2.82)  0.004
rs2143823 (HTR1B) additive T/T 0.42 0.61 1
 0.003C/T 0.27 0.31 0.79 (0.34-1.85)
C/C 0.31 0.09 0.17 (0.06-0.51)
dominant T/T 0.42 0.61 1
 0.046
C/T-C/C 0.58 0.39 0.47 (0.23-0.99)
recessive T/T-C/T 0.69 0.92 1
<0.001
C/C 0.31 0.09 0.18 (0.06-0.53)
log-additive 0.47 (0.28-0.78)  0.003
rs2007153 (DBH) additive G/G 0.21 0.42 1
 0.004A/G 0.49 0.47 0.48 (0.23-1.04)
A/A 0.30 0.11 0.20 (0.07-0.54)
dominant G/G 0.21 0.42 1
 0.007
A/G-A/A 0.80 0.58 0.38 (0.18-0.78)
recessive G/G-A/G 0.70 0.89 1
 0.006
A/A 0.30 0.11 0.31 (0.13-0.74)
log-additive 0.45 (0.28-0.73) <0.001
rs2283123 (DBH) additive C/C 0.89 0.96 1
 0.140C/T 0.10 0.04 0.36 (0.10-1.32)
T/T 0.01 0.00
dominant C/C 0.89 0.96 1
 0.07
C/T-T/T 0.11 0.04 0.32 (0.09-1.15)
recessive C/C-C/T 0.99 1.00 1
 0.25
T/T 0.01 0.00
log-additive 0.33 (0.10-1.12)  0.056
rs11246226 (DRD4) additive A/A 0.74 0.89 1
 0.09A/C 0.24 0.11 0.40 (0.17-0.95)
C/C 0.01 0.00
dominant A/A 0.74 0.89 1
 0.031
A/C-C/C 0.26 0.11 0.39 (0.16-0.94)
recessive A/A-A/C 0.99 1.00 1
 0.560
C/C 0.01 0.00
log-additive 0.39 (0.16-0.94)  0.029
rs4331145 (DRD4) additive A/A 0.36 0.64 1
 0.046A/G 0.62 0.33 0.36 (0.16-0.83)
G/G 0.02 0.04 1.20 (0.09-15.39)
dominant A/A 0.36 0.64 1
 0.022
A/G-G/G 0.64 0.37 0.39 (0.17-0.88)
recessive A/A-A/G 0.98 0.96 1
 0.590
G/G 0.02 0.04 1.98 (0.16-25.08)
log-additive 0.49 (0.23-1.03)  0.055
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Dysregulation of dopaminergic neurotransmission has 
been implicated in several neuropsychiatric diseases in-
cluding schizophrenia, bipolar disease, and attention defi-
cit disorder. Therefore, genes involved in the metabolic 
pathway of dopamine are biologically important candi-
dates in the susceptibility of these disorders. Although a 
large body of data exists in the literature on association be-
tween polymorphisms in dopaminergic genes and schizo-
phrenia, the results are inconsistent (17-21). While the in-
consistent results could be attributed to phenotypic and 
genetic heterogeneity of schizophrenia, many studies con-
sidered a few polymorphisms within a gene based on past 
literature reports.
We pursued a more comprehensive approach of tagging 
the entire gene regions taking the advantage of the Hap-
Map database. TagSNPs were selected on 8 genes that 
include 2 dopamine receptors, DRD5 and DRD4; 2 genes 
involved in dopamine synthesis, TH and DBH; 2 neurotrans-
mitter transporters, SLC6A3 and SLC6A4; a serotonin recep-
rs4320932 (TH) Additive G/G 0.56 0.87 1
 0.001A/G 0.43 0.13 0.19 (0.07-0.51)
A/A 0.02 0.00
Dominant G/G 0.56 0.87 1
<0.001
A/G-A/A 0.44 0.13 0.18 (0.06-0.49)
Recessive G/G-A/G 0.98 1.00 1
 0.25
A/A 0.02 0.00
Log-additive 0.18 (0.07-0.49) <0.001
rs140700 (SLC6A4) Additive G/G 0.77 0.85 1
 0.290A/G 0.18 0.14 0.68 (0.31-1.49)
A/A 0.05 0.01 0.27 (0.03-2.45)
Dominant G/G 0.77 0.85 1
 0.190
A/G-A/A 0.23 0.15 0.61 (0.29-1.28)
Recessive G/G-A/G 0.95 0.99 1
 0.220
A/A 0.05 0.01 0.28 (0.03-2.60)
Log-additive 0.62 (0.33-1.17)  0.130
rs1050565 (SLC6A4) Additive A/A 0.48 0.32 1
 0.160A/G 0.40 0.50 1.74 (0.88-3.42)
G/G 0.13 0.19 2.11 (0.82-5.40)
Dominant A/A 0.48 0.32 1
 0.063
A/G-G/G 0.53 0.68 1.82 (0.96-3.45)
Recessive A/A-A/G 0.88 0.81 1
 0.300
G/G 0.13 0.19 1.57 (0.66-3.75)
Log-additive 1.51 (0.97-2.37)  0.068
rs2020917 (COMT) Additive T/T 0.33 0.33 1
 0.041C/T 0.38 0.55 1.32 (0.63-2.75)
C/C 0.29 0.13 0.44 (0.17-1.12)
Dominant T/T 0.33 0.33 1
 0.850
C/T-C/C 0.67 0.68 0.93 (0.47-1.85)
Recessive T/T-C/T 0.71 0.87 1
 0.016
C/C 0.29 0.13 0.37 (0.16-0.86)
Log-additive 0.72 (0.46-1.12)  0.140
rs165815 (COMT) Additive T/T 0.50 0.31 1
 0.175C/T 0.30 0.49 2.27 (0.94-5.47)
C/C 0.20 0.20 1.75 (0.61-5.03)
Dominant T/T 0.50 0.31 1
 0.076
C/T-C/C 0.50 0.69 2.08 (0.93-4.61)
Recessive T/T-C/T 0.80 0.80 1
 0.747
C/C 0.20 0.20 1.18 (0.45-3.06)
Log-additive 1.42 (0.85-2.36)  0.180
TAble 4. Genotypic associations of 12 significant tag single nucleotide polymorphisms (tagSNP) with schizophrenia susceptibility 
– continued
Genotype Frequency odds ratio
SNP model Genotypes control case (95% confidence interval) P
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tor, HTR1B; and 1 gene involved in dopamine degradation, 
COMT. Forty-nine tagSNPs in these genes were tested for 
association with schizophrenia risk in a Croatian popula-
tion. Our study shows significant allelic association of 12 
tagSNPs with schizophrenia susceptibility in the Croatian 
sample. Eleven of these tagSNPs also show significant ge-
notypic associations. Four of the associated SNPs located 
in DRD5 (rs1850744), HTR1B (rs2143823), DBH (rs2007153), 
and TH (rs4320932) showed significant allelic and genotyp-
ic associations. The remaining 8 SNPs that showed moder-
ate levels of association are located in SLC6A3 (rs464049), 
DBH (rs2283123), DRD4 (rs11246226, rs4331145), SLC6A4 
(rs140700, rs1050565), and COMT (rs2020917, rs165815). We 
further evaluated these 12 tagSNPs under 4 genetic mod-
els (additive, dominant, recessive, and log-additive) to iden-
tify at-risk genotypes. Interestingly, all of 4 most significant-
ly associated SNPs showed significant ORs in at least 2 of 
the genetic models reaffirming the signals of associations. 
While tagSNPs provide a comprehensive assessment of ge-
netic association, haplotype analysis based on tagSNPs is 
not likely to provide consequential information. Note that 
we used tagSNPs based on a pair-wise r2 (≥0.8) among the 
common SNPs within the tagged region that would likely 
render statistical independence among the tagSNPs with 
the possibility of haplotypes being unstable.
A limitation of our study is a comparatively small sample 
size and the results should be considered preliminary. 
However, the observed associations are biologically rel-
evant. Animal model and expression studies have impli-
cated these genes in the metabolism of catecolamines 
(22-25). DRD5 encodes the D5 subtype of the dopamine re-
ceptor, which is expressed in neuron in the limbic regions 
of the brain. HTR1B, located on 6q13-q26, is identified as 
one of the schizophrenia susceptibility gene and is linked 
with many neuropsychiatric diseases (26,27). The protein 
encoded by dopamine beta-hydroxylase (DBH) converts 
dopamine to norepinephrine. Variants in DBH were asso-
ciated with modulation in psychotic symptoms in schizo-
phrenia (28). TH is the rate-limiting step in catecholamine 
biosynthesis (29). Seeman et al (30) suggested involvement 
of dopamine supersensitivity and elevated activity of TH, 
DBH, and DRD4 genes in rat striatal tissue along with eleva-
tion of other dopamine pathway genes. One of the more 
well studied genes in neuropsychiatric disorders is the cat-
echol-O-methyltransferase (COMT) gene, which catalyzes 
the transfer of a methyl group from S-adenosylmethionine 
to catecholamines, including the neurotransmitters dopa-
mine, epinephrine, and norepinephrine. A large case-con-
trol study of Ashkenazi Jews showed highly significant as-
sociation between a COMT haplotype and schizophrenia 
(17). However, the findings have been inconclusive, with 
several studies, including a meta-analysis, showing no 
association (31). We found 2 COMT SNPs (rs2020917 and 
rs165815) that were associated with risk of schizophrenia. A 
recent study reported haplotype-based association of the 
serotonin transporter 5-HTT (SLC6A4) with schizophrenia, 
but failed to find association at single marker level (32). It 
is notable that we found moderate association at 2 SNPs 
(rs140700 and rs1050565) in this gene.
The present study is based on a candidate gene approach. 
It should be noted that, as with other complex diseases, 
genome wide association studies have been initiated to 
identify genetic risk variants associated with psychiatric 
disorders (33). While genome wide associations will poten-
tially uncover the risk variants following an unbiased ap-
proach, candidate gene association studies will be impor-
tant in pursuing the roles of known genes with functional 
implications in the pathophysiology of the disease. How-
ever, a comprehensive assessment of the genetic variation 
within the genes of interest will be important. The tagSNPs 
are not likely to be causal variants, but are rather in statis-
tical associations with putative functional variants. There-
fore, assessment of biological relevance of these indirectly 
associated sequence variants is not imperative; however, 
they provide the basis for further investigation leading to 
the discovery of sequences directly implicated in the dis-
ease pathophysiology.
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